Clinical and genetic delineation of neurodegeneration with brain iron accumulation

Journal of Medical Genetics

Volumn 46, Issue 2, 2009, Pages 73-80

  Gregory, A ^a   Polster, B J ^a   Hayflick, S J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; LEVODOPA; TRIHEXYPHENIDYL;

BRAIN DEPTH STIMULATION; CLINICAL FEATURE; GENE; GENE MUTATION; HUMAN; MOLECULAR GENETICS; NEUROAXONAL DYSTROPHY; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROIMAGING; NEUROPATHOLOGY; PANK2 GENE; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PLA2G6 GENE; PRIORITY JOURNAL; REVIEW;

BRAIN; HUMANS; IRON; NEUROAXONAL DYSTROPHIES; NEURODEGENERATIVE DISEASES; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 62149099955     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2008.061929     Document Type: Review

References (68)

1. Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, Gitschier J. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33-40.
2. Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus pallidus und der Substantia nigra. Z Ges Neurol Psychiatr 1922:79:254-302.
3. Shevell M. Racial hygiene, active euthanasia, and Julius Hallervorden [see comments]. Neurology 1992;42:2214-9.
4. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-9.
5. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995;92:2539-43.
6. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-4.
7. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, Johnson CA, Levinson B, Woods CG, Wilmot B, Kramer P, Gitschier J, Maher ER, Hayflick SJ. PLA2G6, encoding a phospholipase A(2), is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006;38:752-4.
8. Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, Sonek S, Coryell JC, Nguyen TM, Nardocci N, Zorzi G, Rodriguez D, Desguerre I, Bertini E, Simonati A, Levinson B, Dias C, Barbot C, Carrilho I, Santos M, Malik I, Gitschier J, Hayflick SJ. Neurodegeneration associated with genetic defects in phospholipase A2. Neurology 2008;71:1042-9.
9. Ching KH, Westaway SK, Gitschier J, Higgins JJ, Hayflick SJ. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002;58:1673-4.
10. Malandrini A, Cesaretti S, Mulinari M, Palmeri S, Fabrizi GM, Villanova M, Parrotta E, Montagnani A, Montagnani M, Anichini M, Guazzi GC. Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report of two cases without serum lipid abnormalities. J Neurol Sci 1996;140:129-31.
11. Muthane UB, Shetty R, Panda K, Yasha TC, Jayakumar PN, Taly AB. Hallervordern Spatz disease and acanthocytes. Neurology 1999;53:32A.
12. Morphy MA, Feldman JA, Kilburn G. Hallervorden-Spatz disease in a psychiatric setting. J Clin Psychiatry 1989;50:66-8.
13. Szanto J, Gallyas F. A study of iron metabolism in neuropsychiatric patients. Hallervorden-Spatz disease. Arch Neurol 1966;14:438-42.
14. Williamson K, Sima AA, Curry B, Ludwin SK. Neuroaxonal dystrophy in young adults: a clinicopathological study of two unrelated cases. Ann Neurol 1982;11:335-43.
15. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. Arch Neurol 1974;30:70-83.
16. Luckenbach MW, Green WR, Miller NR, Moser HW, Clark AW, Tennekoon G. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. Am J Ophthalmol 1983;95:369-82.
17. Newell FW, Johnson ROd, Huttenlocher PR. Pigmentary degeneration of the retina in the Hallervorden-Spatz syndrome. Am J Ophthalmol 1979;88(3 Pt 1):4B7-71.
18. Roth AM, Hepler RS, Mukoyama M, Cancilla PA, Foos RY. Pigmentary retinal dystrophy in Hallervorden-Spatz disease: clinicopathological report of a case. Survey of Ophthalmology 1971 ;16:24-35.
19. Egan RA, Weleber RG, Hogarth P, Gregory A, Coryell J, Westaway SK, Gitschier J, Das S, Hayflick SJ. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol 2005;140:267-74.
20. Swaiman KF. Hallervorden-Spatz syndrome and brain iron metabolism. Arch Neurol 1991;48:1285-93.
21. Freeman K, Gregory A, Turner A, Blasco P, Hogarth P, Hayflick S. Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intellect Disabil Res 2007;51(Pt. B):417-26.
22. Aicardi J, Castelein P. Infantile neuroaxonal dystrophy. Brain 1979;102:727-48.
23. Kurian MA, Morgan NV, MacPherson L, Foster K, Peake D, Gupta R, Philip SG, Hendriksz C, Morton JE, Kingston HM, Rosser EM, Wassmer E, Gissen P, Maher ER. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008;70:1623-9.
24. Nardocci N, Zorzi G, Farina L, Binelli S, Scaioli W, Ciano C, Verga L, Angelini L, Savoiardo M, Bugiani O. Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria. Neurology 1999;52:1472- 8.
25. Radermecker J, Martin JJ. [Infantile neuro-axonal dystrophy and Hallervorden-Spatz disease. Electro-clinical and anatomo-pathological and differential diagnostic aspects]. Bull Acad R Med Belg 1972;12:459-502.
26. Ferriss GS, Happel LT, Duncan MC. Cerebral cortical isolation in infantile neuroaxonal dystrophy. Electroencephalogr Clin Neurophysiol 1977;43:168-82.
27. Mubaidin A, Roberts E, Hampshire D, Dehyyat M, Shurbaji A, Mubaidien M, Jamil A, Al-Din A, Kurdi A, Woods CG. Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. J Med Genet 2003;40:543-6.
28. Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA. Characterization of PLA2G6 as a locus for dystoniaparkinsonism. Ann Neurol 2008 June 20 [Epub ahead of print].
29. Drayer BP, Burger P, Hurwitz B, Dawson D, Cain J, Leong J, Herfkens R, Johnson GA. Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen. Ann Neurol 1987;22:546- 50.
30. Mutoh K, Okuno T, Ito M, Nakano S, Mikawa H, Fujisawa I, Asato R. MR imaging of a group I case of Hallervorden-Spatz disease. J Comput Assist Tomogr 1988;12:851-3.
31. Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988:24:692-4.
32. Tanfani G, Mascalchi M, Dal Pozzo GC, Taverni N, Saia A, Trevisan C. MR imaging in a case of Hallervorden-Spatz disease. J Comput Assist Tomogr 1987;11:1057-8.
33. Hayflick SJ, Penzien JM, Michl W, Sharif UM, Rosman NP, Wheeler PG. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:166-9.
34. * and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008;70:1614-9.
35. Farina L, Nardocci N, Bruzzone MG, D'lncerti L, Zorzi G, Verga L, Morbin M, Savoiardo M. Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients. Neuroradiology 1999;41:376-80.
36. Ramaekers VT, Lake BD, Harding B, Boyd S, Harden A, Brett EM, Wilson J. Diagnostic difficulties in infantile neuroaxonal dystrophy. A clinicopathological study of eight cases. Neuropediatrics 1987;18:170-5.
37. Barlow JK, Sims KB, Kolodny EH. Early cerebellar degeneration in twins with infantile neuroaxonal dystrophy. Ann Neurol 1989;25:413-5.
38. Ito M, Okuno T, Asato R, Mutoh K, Nakano S, Kataoka K, Fujii T, Mikawa H, Saida K. MRI in infantile neuroaxonal dystrophy. Pediatr Neurol 1989;5:245-8.
39. Tanabe Y, lai M, Ishii M, Tamai K, Maemoto T, Ooe K, Takashima S. The use of magnetic resonance imaging in diagnosing infantile neuroaxonal dystrophy. Neurology 1993;43:110-3.
40. Uggetti C, Egitto MG, Fazzi E, Bianchi PE, Zappoli F, Martelli A, Lanzi G. Transsynaptic degeneration of lateral geniculate bodies in blind children: in vivo MR demonstration. AJNR Am J Neuroradiol 1997;18:233-8.
41. Ishii M, Tanabe Y, Goto M, Sugita K. [MRI as an aid for diagnosis of infantile neuroaxonal dystrophy]. No To Hattatsu 1992;24:491-3.
42. Jellinger K. Neuroaxonal dystrophy: its natural history and related disorders. In: Zimmerman HM, ed. Progress in neuropathology, Vol 2. New York and London: Grune & Stratton, 1973:129-80.
43. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:148-55.
44. Hallervorden J. Uber eine familiare Erkrankung im extrapyramidalen System. Dtsch Z Nervenheilkd 1924;(81):204-210.
45. Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 1998;51:887-9.
46. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gammasynuclein neuropathology. Am J Pathol 2000;157:361-8.
47. Neumann M, Adler S, Schluter O, Kremmer E, Benecke R, Kretzschmar HA. Alphasynuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (Beri) 2000;100:568-74.
48. Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol 1999;58:1263-8.
49. Odawara T, Iseki E, Yagishita S, Amano N, Kosaka K, Hasegawa K, Matsuda Y, Kowa H. An autopsied case of juvenile parkinsonism and dementia, with a widespread occurrence of Lewy bodies and spheroids. Clinical Neuropathology 1992;11:131-4.
50. Saito Y, Kawai M, Inoue K, Sasaki R, Arai H, Nanba E, Kuzuhara S, lhara Y, Kanazawa I, Murayama S. Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 2000;177:48-59.
51. Sugiyama H, Hainfellner JA, Schmid-Siegel B, Budka H. Neuroaxonal dystrophy combined with diffuse Lewy body disease in a young adult. Clin Neuropathol 1993;12:147-52.
52. Tuite PJ, Provias JP, Lang AE. Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease. J Neurol Neurosurg Psychiatry 1996;61:523-7.9
53. Wakabayashi K, Yoshimoto M, Fukushima T, Koide R, Horikawa Y, Morita T, Takahashi H. Widespread occurrence of alpha-synuclein/NACP- immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol Appl Neumbiol 1999;25:363-8.
54. Leonardi R, Rock CO, Jackowski S, Zhang YM. Activation of human mitochondrial pantothenate kinase 2 by palmitoylcarnitine. Proc Natl Acad Sci USA 2007;104:1494-9.
55. Karim MA, Valentine VA, Jackowski S. Human pantothenate kinase 1 (PANK1) gene: characterization of the cDNAs, structural organization and mapping of the locus to chromosome 10q23.2-23.31. Am J Hum Genet 2000;67:A984.
56. Johnson MA, Kuo YM, Westaway SK, Parker SM, Ching KH, Gitschier J, Hayflick SJ. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci 2004;1012:282-98.
57. Hortnagel K, Prokisch H, Meitinger T. An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum Mol Genet 2003;12:321-7.
58. Hartig MB, Hortnagel K, Garavaglia B, Zorzi G, Kmiec T, Klopstock T, Rostasy K, Svetel M, Kostic VS, Schuelke M, Botz E, Weindl A, Novakovic I, Nardocci N, Prokisch H, Meitinger T. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006;59:248-56.
59. Haverfield EV, Dempsey MA, Gregory A, Westaway SK, Hayflick SJ, Das S. Intragenic deletion and duplication analysis of the PANK2 and PLA2G6 genes in patients with NBIA. ACMG Annual Clinical Genetics Meeting. Phoenix, Arizona, USA, 2008.
60. Hong BS, Senisterra G, Rabeh WM, Vedadi M, Leonardi R, Zhang YM, Rock CO, Jackowski S, Park HW. Crystal structures of human pantothenate kinases. Insights into allosteric regulation and mutations linked to a neurodegeneration disorder. J Biol Chem 2007;282:27984-93.
61. Baburina I, Jackowski S. Cellular responses to excess phospholipid. J Biol Chem 1999;274:9400-8.
62. Larsson PK, Claesson HE, Kennedy BP. Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. J Biol Chem 1998;273:207-14.
63. Jellinger K, Seitelberger F, Rosenkranz W. [Infantile neuroaxonal dystrophy. Early form with preferential cerebellar involvement]. Acta Neuropathol (Berl) 1968;10:123-31.
64. Baumeister FA, Auer DP, Hortnagel K, Freisinger P, Meitinger T. The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics 2005;36:221-2.
65. Gallucci M, Cardona F, Arachi M, Splendiani A, Bozzao A, Passariello R. Follow-up MR studies in Hallervorden-Spatz disease. J Comput Assist Tomogr 1990;14:118-20.
66. Lands WE. Metabolism of glycerolipids. 2. The enzymatic acylation of lysolecithin. Biol Chem 1960;235:2233-7.
67. Perez R, Melero R, Balboa MA, Balsinde J. Role of group VIA calcium-independent phospholipase A2 in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. J Biol Chem 2004;279:40385-91.
68. Castelnau P, Cif L, Valente EM, Vayssiere N, Hemm S, Gannau A, Digiorgio A, Coubes P. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005;57:738-41.